Mehdi Shahidi
Welcome, everyone, to this Extraordinary General Meeting of Shareholders of CureVac N.V. My name is Dr. Mehdi Shahidi. I’m a member of the company’s Supervisory Board. And due to a health-related absence of our Chairman, I will chair today’s meeting in accordance with Dutch law and the company’s Articles of Association.
This Extraordinary General Meeting has been convened in connection with BioNTech’s public exchange offer for all outstanding shares of CureVac N.V. During today’s meeting, you will be asked to vote on certain resolutions relating to the proposed transaction with BioNTech, including the post-offer corporate reorganization of CureVac and its subsidiaries and the appointment of new members to CureVac’s Management and Supervisory Board.
Present at this Extraordinary General Meeting, either in person or by phone are, among others, Alexander Zehnder, our CEO; Thaminda Ramanayake, our CBO; Marco Rau, our General Counsel, who will act as Secretary of today’s meeting; representatives working with our Dutch Legal Counsel, NautaDutilh and we, including our civil law notary, Paul van der Bijl.
Before proceeding, I will now give the floor to the Secretary, who will discuss certain legal formalities relating to today’s meeting.
Marco Rau
Thank you, Mehdi. I’m Dr. Marco Rau, the General Counsel, Chief Compliance Officer and the Corporate Secretary of CureVac. For the record, I note that today’s meeting has been convened with due observance of all relevant requirements under applicable law and the company’s Articles of Association.
At this meeting, 156,246,488 shares are represented, which represents approximately 70.52% of the company’s issued share capital. This meeting will be conducted in the English language. We are
Read the full article here